Browse hierarchy: [General, Plastic Surgery (SU)](/submissions/SU) → [Subpart E — Surgical Devices](/submissions/SU/subpart-e%E2%80%94surgical-devices) → [21 CFR 878.4452](/submissions/SU/subpart-e%E2%80%94surgical-devices/878.4452) → PGZ — Non-Absorbable, Expandable, Hemostatic Sponge For Temporary Internal Use

# PGZ · Non-Absorbable, Expandable, Hemostatic Sponge For Temporary Internal Use

_General, Plastic Surgery · 21 CFR 878.4452 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ

## Overview

- **Product Code:** PGZ
- **Device Name:** Non-Absorbable, Expandable, Hemostatic Sponge For Temporary Internal Use
- **Regulation:** [21 CFR 878.4452](/submissions/SU/subpart-e%E2%80%94surgical-devices/878.4452)
- **Device Class:** 2
- **Review Panel:** [General, Plastic Surgery](/submissions/SU)

## Identification

A nonabsorbable expandable hemostatic sponge for temporary internal use is a prescription device intended to be placed temporarily into junctional, non-compressible wounds, which are not amenable to tourniquet use, to control bleeding until surgical care is acquired. The sponges expand upon contact with blood to fill the wound cavity and provide a physical barrier and pressure that facilitates formation of a clot. The device consists of sterile, nonabsorbable radiopaque compressed sponges and may include an applicator to facilitate delivery into a wound.

## Classification Rationale

Class II (special controls). The special controls for this device are:

## Special Controls

In combination with the general controls of the Food, Drug & Cosmetic Act, the Non-absorbable, expandable, hemostatic sponge for temporary internal use is subject to the following special controls:

*Classification.* Class II (special controls). The special controls for this device are:(1) Performance data must demonstrate the biocompatibility of patient-contacting components.
(2) Performance data must demonstrate the sterility of patient-contacting components including endotoxin and pyrogenicity assessments.
(3) Performance data must support device stability by demonstrating continued sterility of the patient-contacting components of the device, package integrity, and device functionality over the requested shelf life.
(4) Assessment of material characteristics must be sufficient to support safety under anticipated conditions of use. Assessments must include the following:
(i) Material specifications.
(ii) Immunogenicity.
(iii) Viral inactivation for animal-derived materials.
(5) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Absorption capacity.
(ii) Extent of swelling.
(iii) Mechanical properties.
(iv) Expansion force/pressure.
(v) Radiopacity.
(vi) Deployment/applicator functionality.
(6) In vivo performance data must demonstrate safe and effective use by verifying that the device performs as intended under anticipated conditions of use. Appropriate analysis/testing must demonstrate that the product: Controls bleeding, does not promote adverse local or systemic effects, and can be completely removed from the wound. The following performance characteristics must be tested:
(i) Deployment.
(ii) Control of bleeding.
(iii) Radiopacity.
(iv) Retrieval.
(v) Assessment of local and systemic effects.
(7) Human factors testing and analysis must validate that the device design and labeling are sufficient for appropriate use by emergency responders deploying the device as well as surgeons retrieving the device from wounds.
(8) Labeling must include:
(i) Specific instructions for deployment by emergency responders and retrieval by surgeons.
(ii) Warnings, cautions, and limitations needed for safe use of the device.
(iii) Information on how the device operates and the typical course of treatment.
(iv) A detailed summary of the in vivo and human factors testing pertinent to use of the device.
(v) Appropriate imaging information to ensure complete retrieval of device.
(vi) An expiration date/shelf life.

## Recent Cleared Devices (7 of 7)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K253290](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ/K253290.md) | XSTAT P15 | Revmedx, Inc. | Nov 12, 2025 | SESE |
| [K210676](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ/K210676.md) | XSTAT 30 Pouch | Revmedx, Inc. | Aug 27, 2021 | SESE |
| [K180051](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ/K180051.md) | XSTAT 30, 1-Pack | Revmedx, Inc. | May 18, 2018 | SESE |
| [K170334](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ/K170334.md) | XSTAT 30, 3-Pack; XSTAT 30, 1-Pack; XSTAT 12, 3 Pack; XSTAT 12, 1 Pack | Revmedx, Inc. | May 1, 2017 | SESE |
| [K161020](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ/K161020.md) | XSTAT-12, 3-Pack, XSTAT-12, 1-Pack | Revmedx, Inc. | Jul 28, 2016 | SESE |
| [K152624](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ/K152624.md) | XSTAT 30, 3-PACK, XSTAT 30, 1-PACK | Revmedx, Inc. | Dec 7, 2015 | SESE |
| [DEN130016](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ/DEN130016.md) | XSTAT | Revmedx, Inc. | Apr 3, 2014 | DENG |

## Top Applicants

- Revmedx, Inc. — 7 clearances

---

**Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/PGZ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com